Effect of Bifidobacterium Triple Viable Bacteria combined with XELOX chemotherapy on intestinal flora and immune function after operation for colorectal cancer
LIU Dan SU Wenzhao WU Zhongliang
Department of General Surgery, the Second Affiliated Hospital of Suzhou University, Jiangsu Province, Suzhou 215000, China
Abstract：Objective To investigate the effect of Bifidobacterium Triple Viable Bacteria combined with Oxaliplatin and Capecitabine (XELOX) chemotherapy on intestinal flora and immune function after operation for colorectal cancer. Methods From February 2016 to February 2019, 93 cases with colorectal cancer after operation admitted to the Second Affiliated Hospital of Suzhou University were selected. According to the random number table method, they were divided into study group (47 cases) and control group (46 cases). Surgical treatment were received in both groups, and control group was given XELOX chemotherapy after surgery, study group was given Bifidobacterium Triple Viable Bacteria on the basis of control group. The clinical effect was evaluated after treatment. The immune function, intestinal flora and the improvement of serum tumor markers were compared in two groups. The occurrence of adverse reactions during treatment in two groups were recorded. Results After two cycles of treatment, the total effective rate of study group was higher than that of control group, the difference was statistically significant (P < 0.05). The lactobacillus, bifidobacterium of study group were higher than those of control group, the escherichia coli and enterococcus faecalis of study group were lower than those of control group, the differences were statistically significant (all P < 0.05). CD4+ and CD4+/CD8+ of study group were lower than those of control group, CD8+ was higher than that of control group, the differences were statistically significant (all P < 0.05). Carbohydrate antigen 199 and carcino-embryonic antigen of study group were lower than those of control group, the differences were statistically significant (all P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Bifidobacterium Triple Viable Bacteria combined with XELOX chemotherapy is effective in the treatment of colorectal cancer. It can effectively improve the intestinal flora, immune function and reduce serum tumor markers, and it is safe and effective.
刘丹 粟文钊 吴忠良. 双歧杆菌三联活菌联合XELOX化疗对大肠癌术后肠道菌群及免疫功能的影响[J]. 中国医药导报, 2019, 16(32): 119-122.
LIU Dan SU Wenzhao WU Zhongliang. Effect of Bifidobacterium Triple Viable Bacteria combined with XELOX chemotherapy on intestinal flora and immune function after operation for colorectal cancer. 中国医药导报, 2019, 16(32): 119-122.
[1] Mazewski C，Kim MS，Gonzalez de Mejia E. Anthocyanins，delphinidin-3-O-glucoside and cyanidin-3-O-glucoside，inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico [J]. Sci Rep，2019，9（1）：11560.
[2] 舒密.间期大肠癌临床和分子学特征的研究进展[J].医学研究生学报，2018，31（9）：1005-1008.
[3] 黄新成，王玉斌，徐臣光，等.卡培他滨单药或联合奥沙利铂同步放化疗对晚期直肠癌的临床疗效研究[J].中国临床药理学杂志，2016，32（2）：129-131.
[4] 曹萍，于成功.双歧杆菌三联活菌散对感染性腹泻患者肠道菌群和炎症因子的影响[J].中国生化药物杂志，2015，36（6）：62-64，67.
[5] 吴驻林，谭婉君，连宝涛，等.复方苦参注射液联合含奥沙利铂化疗方案治疗大肠癌疗效与安全性的系统评价[J].中国药房，2017，28（3）：369-373.
[6] 张维晴，吴驻林，何力，等.康艾注射液辅助化疗治疗大肠癌的meta分析[J].国际中医中药杂志，2018，40（7）：616-621.
[7] 谢德金，王小忠，彭云恒，等.经内镜支架置入联合腹腔镜手术治疗左侧大肠癌性梗阻的临床价值[J].腹腔镜外科杂志，2016，21（11）：832-836.
[8] 陈洪兴.肝动脉灌注化疗及栓塞联合口服希罗达对大肠癌伴肝转移患者的疗效观察[J].中国现代医学杂志，2015，25（4）：48-51.
[9] Liu X，Liu L，Dong Z，et al. Expression patterns and prognostic value of m6A-related genes in colorectal cancer [J].Am J Transl Res，2019，11（7）：3972-3991.
[10] 张帆，罗庆锋.结肠癌根治术后FOLFOX或XELOX化疗的Ⅱ、Ⅲ期老年患者无复发生存期和总生存期及其影响因素分析[J].临床和实验医学杂志，2018，17（8）：853-856.
[11] 史晓艳.双歧杆菌对化疗后肠道菌群紊乱及相关性肠炎的防治[D].大连：大连医科大学，2017.
[12] 王永卫，陈卫挺.添加益生菌的早期肠内营养鼻饲治疗对危重病患者营养状况及肠黏膜屏障的影响[J].中国现代医生，2019，57（8）：80-83.
[13] 玉海.ERCC1和ERCC2基因多态性与胃癌易感性及晚期胃癌患者奥沙利铂化疗预后的相关关系[D].广州：南方医科大学，2017.
[14] Lyskj?覸r I，Kronborg CS，Rasmussen MH，et al. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer [J]. Sci Rep，2019，9（1）：11542.
[15] 潘勇.大肠癌右半结肠切除患者肠道菌群变化及意义[J].山东医药，2017，57（12）：48-50.
[16] 张育娟，周泽建，黄日妹，等.大肠癌术后肠道菌群术前补充双歧三联活菌的影响分析[J].海峡药学，2015，27（10）：155-156.
[17] 邵云娣，路娜娜，赵敏，等.益生菌对结肠癌化疗患者肠道菌群及化疗相关并发症影响的研究[J].中国现代医生，2018，56（2）：23-26.
[18] 李国庆.补充双歧三联活菌对大肠癌术后肠道菌群影响的研究[J].中国现代医生，2011，49（27）：82-84.
[19] Chen W，Lian W，Yuan Y，et al. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress [J]. Cell Death Dis，2019， 10（8）：600.
[20] Wang D，Yang L，Yu W，et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling [J].J Immunother Cancer，2019，7（1）：215.
[21] Keramida K，Charalampopoulos G，Filippiadis D，et al. Cardiovascular complications of metastatic colorectal cancer treatment [J]. J Gastrointest Oncol，2019，10（4）：797-806.
[22] 林伟章，李书超，邓亮，等.不同类型肠易激综合征患者肠道菌群分布差异及肠道微生态制剂干预效果观察[J].中国基层医药，2017，24（22）：3364-3368.
[23] 刘学进，陈垦.双歧杆菌三联活菌胶囊联合肠内营养治疗急性重症胰腺炎的临床观察[J].安徽医药，2018，22（10）：2008-2010.
2019, Vol. 16 
京公网安备 11010502046598号